Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS

NCT00302341 is registered in ClinicalTrials.gov with Immtech Pharmaceuticals, Inc as lead sponsor.

NCT NCT00302341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00302341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS
Lead sponsor
Immtech Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2006
Completion date
December 31, 2008
Enrollment
48 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, pneumocystis carinii pneumonia, pneumonia, interstitial plasma cell, pneumonia, pneumocystis carinii